IP Library › Granted Patent US 9,982,263
Granted Patent B2
US 9,982,263 · App. 14/921,510 · Granted May 29, 2018

Conserved HBV and HCV sequences useful for gene silencing

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,982,263
App. No.
14/921,510
Granted
May 29, 2018
Kind
B2
Abstract

Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.

Claims (2)

1. A method for inhibiting expression of a polynucleotide sequence of hepatitis B virus in an in vivo mammalian cell comprising administering to said cell at least one double-stranded RNA effector molecule comprising a sequence targeted to at least 19 contiguous nucleotides within coordinates 2791-2811 of Genbank accession number V01460 (SEQ ID NO: 266).

2. The method of claim 1 , wherein the mammalian cell is a human cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2020
From: PACHUK, CATHERINE J.; SATISHCHANDRAN, CHANDRASEKHAR; ZURAWSKI, VINCENT R., JR.; MINTZ, LIAT
To: NUCLEONICS, INC.
Reel/Frame 052553/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2020
From: NUCLEONICS, INC.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 052553/0379 →